StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Prakash Gaba

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

byPrakash GabaHorizon: NA (inferred Intraday)21 Oct 2026, 9:37 am ISTvia CNBC Awaaz.

Entry₹2,246Inferred
Target₹2,300
Total upside +2.40% (call closed)
Stop loss₹2,230-0.71% risk
Exit₹2,23021 Oct 2026, 9:49 am
Stop-loss hit-0.71%
Follow Prakash Gaba for new calls(19% target hit, 375 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 21 Oct 2026
3 supporting1 opposing
Supports the BUY call (3)

2 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·19 Oct · yesterday

Glenmark Pharmaceuticals Launches GLIPIQ® (Semaglutide) in India with Weekly Treatment Starting at ₹325

NewsGoogle News·19 Oct · 2d ago

(opens in new tab)

Glenmark Pharma's biotech arm IGI unveils ISB 2301 to target solid tumors

NewsGoogle News·17 Oct · 4d ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Glenmark USA settles antitrust suits for $29.628 million

NewsGoogle News·18 Oct · 2d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Prakash Gaba

Every call and its outcome